Wall Street brokerages forecast that Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) will announce earnings of ($0.86) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Trillium Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.75) and the lowest estimate coming in at ($1.07). Trillium Therapeutics reported earnings per share of ($0.78) during the same quarter last year, which suggests a negative year-over-year growth rate of 10.3%. The company is expected to report its next earnings results on Thursday, November 9th.

On average, analysts expect that Trillium Therapeutics will report full-year earnings of ($3.91) per share for the current year, with EPS estimates ranging from ($4.78) to ($2.89). For the next year, analysts expect that the firm will post earnings of ($3.17) per share, with EPS estimates ranging from ($3.88) to ($2.72). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that that provide coverage for Trillium Therapeutics.

TRIL has been the topic of several recent research reports. Zacks Investment Research lowered shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, September 1st. HC Wainwright initiated coverage on shares of Trillium Therapeutics in a research note on Monday, July 17th. They issued a “buy” rating and a $7.00 price target on the stock. Finally, Cowen and Company reiterated a “buy” rating on shares of Trillium Therapeutics in a research note on Wednesday, July 5th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average target price of $15.00.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.americanbankingnews.com/2017/10/16/brokerages-expect-trillium-therapeutics-inc-tril-to-announce-0-86-eps.html.

Trillium Therapeutics (NASDAQ:TRIL) traded down 0.83% during trading on Monday, hitting $6.00. 174,766 shares of the stock were exchanged. Trillium Therapeutics has a 12-month low of $4.15 and a 12-month high of $15.87. The stock has a 50 day moving average price of $5.08 and a 200-day moving average price of $5.15. The firm’s market capitalization is $64.76 million.

Institutional investors have recently added to or reduced their stakes in the company. NEA Management Company LLC acquired a new position in shares of Trillium Therapeutics during the 2nd quarter worth about $4,619,000. Victory Capital Management Inc. increased its stake in shares of Trillium Therapeutics by 88.9% during the 2nd quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 68,970 shares during the last quarter. K2 Principal Fund L.P. acquired a new position in shares of Trillium Therapeutics during the 2nd quarter worth about $264,000. Wells Fargo & Company MN increased its stake in shares of Trillium Therapeutics by 34.1% during the 1st quarter. Wells Fargo & Company MN now owns 17,700 shares of the biotechnology company’s stock worth $109,000 after purchasing an additional 4,500 shares during the last quarter. Finally, Sectoral Asset Management Inc increased its stake in shares of Trillium Therapeutics by 42.9% during the 2nd quarter. Sectoral Asset Management Inc now owns 183,272 shares of the biotechnology company’s stock worth $806,000 after purchasing an additional 55,000 shares during the last quarter. Institutional investors own 47.97% of the company’s stock.

Trillium Therapeutics Company Profile

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.